Germany Insulin Delivery Market Outlook to 2025

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 What Is This Report About? 5

2.2 Insulin Delivery Market Segmentation 5

2.3 Definitions of Markets Covered in the Report 6

3 Insulin Delivery Market, Germany 7

3.1 Insulin Delivery Market, Germany, Revenue ($m), 2015-2025 7

3.1.1 Insulin Pens Market, Germany, Revenue ($m), by Segment, 2015-2025 9

3.1.2 Insulin Pumps Market, Germany, Revenue ($m), by Segment, 2015-2025 11

3.2 Insulin Delivery Market, Germany, Volume (Units), 2015-2025 13

3.2.1 Insulin Pens Market, Germany, Volume (Units), by Segment, 2015-2025 15

3.2.2 Insulin Pumps Market, Germany, Volume (Units), by Segment, 2015-2025 17

3.3 Insulin Delivery Market, Germany, Average Price ($), 2015-2025 19

3.4 Insulin Delivery Market, Germany, Distribution Share by Revenue ($m), 2019 20

3.5 Insulin Delivery Market, Germany, Company Share by Revenue ($m), 2019 21

4 Overview of Key Companies in Germany, Insulin Delivery Market 23

4.1 Novo Nordisk AS 23

4.1.1 Company Overview 23

4.2 Sanofi 23

4.2.1 Company Overview 23

4.3 Eli Lilly and Co 23

4.3.1 Company Overview 23

4.4 Medtronic Plc 24

4.4.1 Company Overview 24

4.5 F. Hoffmann-La Roche Ltd 24

4.5.1 Company Overview 24

4.6 Ypsomed Holding AG 24

4.6.1 Company Overview 24

4.7 Insulet Corp 25

4.7.1 Company Overview 25

5 Insulin Delivery Market Pipeline Products 26

6 Financial Deals Landscape 27

6.1 Debt Offerings 27

6.1.1 Bayer Raises USD1.1 Billion in Private Placement of

2.375% Bonds Due 2079 27

6.1.2 Bayer Raises USD830.7 Million in Private Placement of

3.125% Bonds Due 2079 28

7 Recent Developments 29

7.1 Corporate Communications 29

7.1.1 Feb 22, 2020: Bayer Cares Foundation donates over EUR 363,000 to support 94 social projects in 32 countries worldwide 29

7.1.2 Sep 10, 2019: Bayer reduces size of board of management from seven to five members 29

7.1.3 Sep 03, 2019: Bayer appoints Marianne De Backer Head of Pharmaceuticals Business Development & Licensing and Member of Executive Committee 30

7.1.4 Apr 16, 2019: Ginkgo Bioworks appoints former Bayer CEO Marijn Dekkers as Chairman of its Board of Directors 31

7.1.5 Apr 12, 2019: Dr. Monika Lessl to lead both the Bayer Science and the Bayer Cares Foundations 31

7.2 Financial Announcements 32

7.2.1 Jul 30, 2019: Bayer on track in operational business 32

7.3 Other Significant Developments 34

7.3.1 Feb 27, 2020: Bayer reaches agreement with stockholder Prof. Strenger on voluntary special audit of due diligence procedures 34

7.3.2 Dec 10, 2019: Bayer to significantly step-up its sustainability efforts 35

7.3.3 Oct 21, 2019: CRISPR Therapeutics and Bayer announce an update on Casebia Therapeutics 37

7.3.4 May 23, 2019: Ypsomed increases EBIT and invests in long-term profitability 37

7.3.5 Apr 25, 2019: Bayer: strong operational start to the year 39

7.4 Strategy And Business Planning 42

7.4.1 Aug 22, 2019: Ypsomed opens production plant in Schwerin 42

8 Appendix 44

8.1 Research Methodology 45

8.1.1 Coverage 45

8.1.2 Secondary Research 45

8.1.3 Primary Research 46

8.1.4 Market Modeling and Forecasting 47

8.1.5 Company Share Analysis 48

8.1.6 Distribution Share Analysis 48

8.1.7 Benchmarking 49

8.2 GlobalData Consulting 49

8.3 Contact Us 50

8.4 Disclaimer 50